Metraipolis › archive › dc_7df4a14908a7

Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications — Europe PMC PMID:41837169

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41837169
DOI
10.1039/d6ra01711h
License (as archived)
solo-consultazione
Archived
2026-11-04T10:18:42.677Z
SHA-256 of the archived text
79a89221df6224dacf616ef5cc9785558ad64d06ebe02ccc87cf2ddf824dc560
Stable URL of this page
https://metraipolis.com/documento/dc_7df4a14908a7

How to cite

Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications — Europe PMC PMID:41837169 — Europe PMC (en), https://europepmc.org/article/MED/41837169 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7df4a14908a7 (Metraipolis archive dc_7df4a14908a7, sha256 79a89221df6224dacf616ef5cc9785558ad64d06ebe02ccc87cf2ddf824dc560)
BibTeX
@misc{dc7df4a14908a7,
  title = {Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications — Europe PMC PMID:41837169},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41837169},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7df4a14908a7; sha256 79a89221df6224dacf616ef5cc9785558ad64d06ebe02ccc87cf2ddf824dc560},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41837169. Agents can read the archived copy with the MCP tool read_document.